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Innovations
Theravance
Medicines that Make a Difference
says Humphrey. “Instead, it is ratio- name change about a year ago, and
its technology focus is now onnal medicinal chemistry, where we
smaller constructs, like bivalentknow the target sites we are going
Theravance believes in its mission
statement so strongly that they have
trademarked it. This South San Fran-
cisco-based company, intent on dis- constructs.after and are only creating mole-
covery and development of best-in- Big Pharma Experiencecules intended to bind in a better
class blockbuster medicines, has a It also helps Theravance’s drug de-way to those sites.” The company
powerhouse in its Board of Direc- velopment efforts to have P. Roy Va-hopes that these improvements in
tors, its scientific team, and its drug gelos, MD, former Merck CEO andselectivity and specificity will reduce
development candidates, all thanks Board Chairman, as a cofounder andunwanted side effects from nonspe-
to the concept of more is better. In Chairman of the Board. In 1996, Va-cific binding. “Improvement in po-
Theravance language, this means gelos immediately set about recruit-tency and duration of action are
multivalency. ing a number of highly experiencedadded potential benefits,” adds
Multivalency senior executives from big pharma.Humphrey.
“Multivalency is a philosophy within “We have really been functionally
chemistry,” according to Mathai operational for about five years
Mammen, MD, a Theravance co- now,” says CEO Rick Winningham,
“We do not do randomfounder and Director of Medicinal a former Bristol-Myers Squibb exec-
utive, who has been on board sinceChemistry. Theravance is building screening. Instead, it is
on the concept of polyvalent entities late 2001. In 2001, Pat Humphrey, arational medicinal chem-
described by George Whitesides, 30-year Glaxo executive, assumed
istry, where we know thePhD, Harvard and MIT researcher the top research position at Thera-
vance, a company he describes asand Theravance cofounder. These target sites we are going
entities were polymers displaying “a drug discovery powerhouse pop-after and are only creat-multiple copies of the same ligand ulated by dedicated drug hunters.”
ing molecules intended toon their backbone. Each identical Theravance’s commercial develop-
ment team is led by David Brinkley,chemical moiety had the same func- bind in a better way to
tion and bound to a defined target. Senior Vice President of Commercialthose sites.”“What we are doing is a bit different Development, who joined the team
—Patrick Humphrey, PhD,in that we are identifying different, in 2000 after leaving Pfizer, where
he was the senior marketing execu-well-defined binding sites on biolog- DSc, Executive V.P. of
ical targets that have not been ex- tive for the Viagra product.Research, Theravanceploited before for various reasons,” Validated Targets and Best-in-
says Mammen. Theravance re- Class Medicines
searchers then develop small mole- “We have the insight of multivalency
Bicoastal Rootscule drug compounds using a biva- applied to validated targets, and we
The seed idea for Theravance, nowlent or multivalent approach rather do it with people who have a great
the corporate home to more thanthan using the large polyvalent con- deal of both passion and experience
200 employees, started years ago instructs that were intriguing to com- in the industry, ” says Winningham.
academic labs working on the poly-pany founders. “We are dialing in Researchers start by focusing on
valent concept. In two research in-superior selectivity and specificity, ” biological mechanisms known to
stitutes on opposite coasts, re-he says, “and in the process creating have yielded successful medicines
searchers John Griffin (Stanford)small molecules that will attach to in the past. “We know that if we af-
and Mathai Mammen (Harvard) weretwo or more sites on a target.” fect that target, that biological
working on the idea, developed“When I first heard about multiva- mechanism, a response will occur
years earlier, that multiple ligands orlency, I thought you might get non- providing therapeutic benefit.” With
drug targets bound together some-specific binding with the additional multivalency, Theravance hopes to
how provides advantageous bindingbinding sites, but it is actually quite avoid some of the problems associ-
specificity potency millions of foldthe opposite,” explains Patrick ated with earlier medications, such
higher than the ligands on their own.Humphrey, PhD, DSc, Executive as unwanted side effects and inade-
“That idea was developed on a poly-Vice President of Research at Thera- quate potency or duration of action.
valent construct,” explains Mam-vance. “We get more specificity be- “All of those shortcomings with ex-
men, “and eventually enabled thecause the secondary binding site(s) isting medicines provide us with op-
initial round of financing that startedis equally unique to the targeted pro- portunity,” Winningham says.
the company, then called Advancedtein(s) as the first.” “With multivalency, we’re able to
improve on potency, selectivity, and“We do not do random screening,” Medicine.” Theravance opted for its
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duration of action: the three main novel mechanism of action that has lead candidates from that program,
now in phase I testing, is on trackareas we focus on, ” says Brinkley. not been demonstrated with any
other clinically used antiinfective,”“We look at markets that we feel are for phase II by year end. Another is
poised to initiate phase I testing latercurrently ill served by the market says Ken Pitzer, DVM, Senior Di-
rector of Commercial Development.leader and could be significantly this year.
Future Programsaided by a next-generation com- Because of the drug’s multiple
mechanisms of action, it appears topound that has some improvement Theravance has another respiratory
program in anticholinergic bron-in one or more of those key fea- be rapidly bactericidal against
gram-positive organisms, especiallytures.” chodilators, the long-acting inhaled
muscarinic antagonists. “Through“Our objective is to go for best- methicillin-resistant Staphylococ-
cus aureus (MRSA) and other similarin-class medications,” explains Win- multivalency, we have managed to
make a wide range of molecules toningham. So it is not surprising that resistant strains. “The hope is that
by having a rapidly bactericidalthe company’s first corporate alli- bind with the five different types of
muscarinic receptors with all sortsance with a major pharma company, drug, patients will not have to be on
therapy as long as they traditionallyGlaxoSmithKline (GSK), is in the field of activity patterns,” says Mammen.
“We use those selectivity patternsof longer-acting 2-adrenoceptor are with drugs like vancomycin,”
adds Brinkley. He hopes that fasteragonists, one of the backbone treat- to our advantage to first understand,
then target a variety of illnesses, in-ments for chronic asthma and infection resolution with multiple
drug actions will reduce the likeli-COPD. In January 2003, the compa- cluding COPD and asthma.” The
company is developing muscarinicnies announced their plan to pool hood of resistance developing or at
least slow it down.compounds and resources to devel- antagonists for overactive bladder
as well. “There is a chance one ofop improvements to the current Longer-Acting -Agonists
Behind Arbelic is the joint Thera-asthma blockbuster medications, those drugs will be in phase I by year
end also, ” says Brinkley. Behind theSerevent (salmeterol) and Advair vance/GSK longer-acting 2-adre-
noceptor agonist program. “When(combination salmeterol/fluticasone respiratory projects, which also in-
clude an inhaled PDE4 inhibitor pro-therapy), both manufactured by we first approached the program,
we did so almost out of a sense ofGSK. “In drug class after drug class, gram, are an intravenous anesthetic
and a gastric motility research effort.the second- or third-generation drug curiosity to see how mutivalency
could address signaling motifs inhas done substantially better than “Multivalency continues to evolve,”
says Mammen. “It puts us down path-the first,” says Brinkley, “and there 7-transmembrane G-protein-coupled
receptors,” explains Edmund Moran,is a lot of benefit to be brought to ways of drug discovery that are not
typical. We use multivalency not justpatients.” Not incidentally, this PhD, Vice President of Medicinal
Chemistry at Theravance. “Thetranslates into a lot of money to be because of the kind of compound
that can come out the other end,made for the company that does it. 2-adrenoceptor, a 7-transmem-
brane receptor, is very well de-Antibiotics in the Lead but we treat it as a philosophy that
generates lead structures for us that“It is clear in practice that multiva- scribed in the literature with two
well-known drugs, the rescue bron-lency delivers drugable molecules at are fundamentally different.”
When Vagelos joined the Thera-an impressive rate,” says Humphrey. chodilator drug albuterol (an agonist
for the receptor) and salmeterol (aTheravance has advanced six com- vance effort, he helped take a core
scientific innovation in polyvalencypounds to drug development candi- long-acting version of that, now a
key component in the Advair prod-dates, all discovered in the last three and began translating it immediately
into medical terms and drug devel-years. The lead candidate, Arbelic uct), available to stimulate it.”
By the late 1990s, several studies(TD-6424 for injection), an intrave- opment opportunities. “We learned
to design forward-looking plansnous antibiotic, entered phase II tri- began to suggest that receptor di-
merization played an important roleals in April 2003. early on in our discovery phase to
get these drugs to market,” says“An important facet of multiva- in the signaling of the 2 adrenocep-
tor. “We attempted to capture thislency is its potential to deliver multi- Brinkley. Adding, as only as a senior
marketing guy can, “Our aim is notfunctionality,” says Humphrey. Ar- receptor dimerization motif with a di-
meric molecule capable of bindingbelic is just one example of several just to get to the clinic with com-
Theravance projects where the drug to adjacent interreceptor agonist pounds. We want to get through it.”
is designed to bind to two or more binding sites,” says Moran. “This
Chemistry & Biology invites yourfundamentally distinct protein tar- search led us to eventually discover
comments on this topic. Pleasegets. “Providing the targets are ap- a series of small molecules that ap-
write to the editors at chembiol@propriate to allow binding to both peared to bind to two sites within
cell.com.with a single molecule, you get bi- the  receptor rather than binding in
an interreceptor fashion. We werefunctionality,” says Humphrey. Alice A. McCarthy is a freelance science
Arbelic appears to have the clas- looking for a molecule like this to writer based in Gloucester, MA (alice@
sic glycopeptide or vancomycin- perhaps lead to a once-a-day in- alicemccarthy.com).
type activity, inhibiting cell wall syn- haled medicine.” Salmeterol cur-
rently requires twice-daily dosing.thesis. “The unique twist is that this
molecule also penetrates into the The result of that agonist discovery
program are the compounds now inbacterial cell membrane and inhibits
phospholipid synthesis, which is a development with GSK. One of the
